First Bank & Trust Sells 2,280 Shares of Catalent, Inc. (NYSE:CTLT)

First Bank & Trust cut its stake in shares of Catalent, Inc. (NYSE:CTLT) by 30.0% during the 1st quarter, Holdings Channel reports. The fund owned 5,326 shares of the company’s stock after selling 2,280 shares during the period. First Bank & Trust’s holdings in Catalent were worth $301,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Gladius Capital Management LP bought a new position in Catalent during the third quarter worth $28,000. GAMMA Investing LLC acquired a new position in Catalent during the fourth quarter worth $33,000. Cary Street Partners Investment Advisory LLC raised its holdings in Catalent by 1,162.3% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after buying an additional 709 shares during the last quarter. Rakuten Securities Inc. acquired a new position in Catalent during the fourth quarter worth $46,000. Finally, Federated Hermes Inc. acquired a new position in Catalent during the fourth quarter worth $46,000.

Catalent Trading Down 0.3 %

Shares of CTLT stock opened at $56.23 on Friday. The firm has a 50-day moving average of $55.56 and a 200-day moving average of $53.86. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. Catalent, Inc. has a one year low of $31.80 and a one year high of $60.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.36). The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. On average, equities research analysts anticipate that Catalent, Inc. will post -0.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CTLT. Stephens restated an “equal weight” rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, April 4th. Barclays upped their price objective on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday. Finally, StockNews.com started coverage on shares of Catalent in a report on Sunday. They set a “sell” rating on the stock. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $55.65.

Insider Activity at Catalent

In related news, insider Ricky Hopson sold 1,401 shares of the stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the transaction, the insider now owns 20,617 shares in the company, valued at $1,118,678.42. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.31% of the stock is owned by company insiders.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.